Dave Matthews

2020 Bionow Oncology Conference

Poster presentation by Dr. Richard Lewis, Demuris Limited “An actinomycete derived natural product compound targeting FOXO transcription factors in acute myeloid leukaemia“ Alderley Park Conference Centre, Thursday 19th March, 2020

Demuris is Commercial Partner in MRC Grant to Newcastle University

£800,000 grant for optimization of novel antibiotics targeting multidrug-resistant tuberculosis. Newcastle, UK – September 11, 2019 – Demuris Limited, a company focused on the discovery and optimization of novel, bioactive compounds from natural sources today announced the successful receipt of a grant from the Medical Research Council to fund work at Newcastle University. Demuris is the …

Demuris is Commercial Partner in MRC Grant to Newcastle University Read More »

Demuris and Newcastle University enter into Funded Collaboration with Morningside Ventures

Focused on the development of novel therapeutics for mitochondrial diseases. Newcastle, UK – 2 August 2019 – The Wellcome Centre for Mitochondrial Research (WCMR) at Newcastle University and Demuris Limited have entered into a collaboration agreement related to the development of novel therapies to treat mitochondrial diseases. This agreement is funded by Morningside Ventures and is …

Demuris and Newcastle University enter into Funded Collaboration with Morningside Ventures Read More »

Innovate UK Grant to Fund Development of Novel Antibiotics for Drug Resistant TB Awarded to Demuris

Demuris has secured a £342,160 grant from Innovate UK to continue the development of a novel class of antibiotics for the treatment of multi-drug resistant Mycobacterium tuberculosis (MDR-TB). Demuris, in collaboration with Newcastle University, has discovered a series of novel natural product antibiotics related to a rifamycin analogue called Kanglemycin1. Semi-synthetic rifamycin antibiotics (rifampicin, rifabutin) …

Innovate UK Grant to Fund Development of Novel Antibiotics for Drug Resistant TB Awarded to Demuris Read More »

Demuris Receives SBRI Innovate UK Grant to Identify Novel Treatments for Gram Negative Infections

Demuris has secured a £342,000 grant, funded by the Department for Health and Social Care (DHSC), from Innovate UK’s SBRI program to identify new treatments for Gram Negative infections. Gram-negative bacteria, such as Escherichia coli and Pseudomonas aeruginosa, pose a significant scientific challenge because their unique “outer membrane” makes it difficult for most antibiotics to work effectively. New …

Demuris Receives SBRI Innovate UK Grant to Identify Novel Treatments for Gram Negative Infections Read More »

Demuris and collaborators identify antibiotic with potential to treat Multi-Drug-Resistant Tuberculosis

Demuris Ltd, in collaboration with UK and US scientists, have identified an antibiotic that may have potential in treating the 600,000 cases per year of Multi-Drug-Resistant Tuberculosis (MDR-TB). The World Health Organisation (WHO) estimates that someone dies from TB every 20 seconds, or around 1.7 million people per year. Mycobacterium tuberculosis is the causative agent …

Demuris and collaborators identify antibiotic with potential to treat Multi-Drug-Resistant Tuberculosis Read More »

Demuris awarded £204,000 grant funding from Innovate UK

Demuris has secured £204,398 grant funding from Innovate UK to develop new molecular methods for global activation of cryptic biosynthetic gene clusters. Actinobacterial Natural Products are an important source of commercially used compounds, including many clinically used antibiotic, antifungal and anticancer compounds. The genes required to produce these compounds are encoded by Biosynthetic Gene Clusters (BGCs). Genomic …

Demuris awarded £204,000 grant funding from Innovate UK Read More »